Facility Design and Engineering

Jun 22, 2018
By Pharmaceutical Technology Editors
The company has completed the first phase of expansion at its headquarters in Freiburg, Germany, in anticipation of increasing demand as cell and gene therapies approach commercialization.
Jun 21, 2018
By Pharmaceutical Technology Editors
The contract development and manufacturing company has received an additional approval from Health Canada to manufacture monoclonal antibody drug substance at its first plant in Icheon, South Korea.
Jun 07, 2018
By Pharmaceutical Technology Editors
The company will provide the first FlexFactory manufacturing platform for TCR T-cell therapy manufacturing.
May 31, 2018
By Pharmaceutical Technology Editors
Ingenza, in partnership with the University of Dundee and Drochaid Research Services, will work on a project to recycle CO2 emissions from bioprocessing plants to serve as feedstock and energy inputs.
May 29, 2018
By Pharmaceutical Technology Editors
This marks the third FDA approval for the company’s second biomanufacturing plant in Incheon, Korea.
May 25, 2018
By Pharmaceutical Technology Editors
The gene therapy company is expected to invest $55 million in a new manufacturing facility that will produce therapies for rare neurological genetic diseases.
May 17, 2018
Vetter's FOYA award-winning facility is an example of a flexible pharmaceutical and biopharmaceutical modular facility design that allows expansion of space without affecting existing operations.
May 16, 2018
By Pharmaceutical Technology Editors
The company is increasing its cell culture media production capacity at its facilities in Pasching, Austria, and Logan, Utah.
May 01, 2018
By Pharmaceutical Technology Editors
As Astellas Pharma winds down its Agensys research operations, the company sells the Santa Monica, CA, facility to Gilead.
Apr 17, 2018
By Pharmaceutical Technology Editors
The company is launching a new pre-fabricated, ready-to-run manufacturing facility that is expected to significantly decrease the production timeline for viral vector-based therapeutics.
native1_300x100
lorem ipsum